Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

NY Times Interview With Sebelius: "I'm Very Encouraged"
Health and Human Services Secretary Kathleen Sebelius, spoke to The New York Times about the state of health care reform on Capitol Hill during a 15-minute interview.
generic viagra online
Rigel's R788 Evaluated In Phase 2 Trial In Multiple Cancers
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. This open-label, single arm clinical trial will include patients with advanced colorectal, thyroid, non-small cell lung, hepatocellular, head and neck, or renal cell cancers who have failed to respond to at least one line of therapy.
News of the day
If A Diet Is Bad For The Teeth It Is Also Bad For The Body
Dental disease may be a wake-up call that your diet is harming your body.
Cardiovascular

Society Welcomes Decision On Ephedrine And Pseudoephedrine

The Royal Pharmaceutical Society welcomed the decision by the Medicines and Healthcare Products Regulatory Agency that medicines containing ephedrine and pseudoephedrine should retain their status as pharmacy (P) medicines. President Steve Churton said: "We are delighted at the MHRA"s decision to keep cold and flu remedies containing ephedrine and pseudoephedrine as pharmacy (P) medicines. "The decision is a ringing endorsement of the vigilance pharmacists have shown in monitoring and controlling the sale of these products. "Pharmacists are experts in medicines and experienced in dealing with medicines liable to misuse. The MHRA"s decision is great news for consumers and provides a clear signal of faith in the pharmacy profession. "I urge pharmacists to continue to remain alert to the supply of these medicines so that they continue to keep their P status". Notes The MHRA have taken this decision taken following the review by the Commission on Human Medicines (CHM) of the measures introduced from July 2007 to control the risk of misuse of OTC medicines containing pseudoephedrine and ephedrine, in the manufacture of the Class A controlled drug methylamphetamine http://www.mhra.gov.uk Royal Pharmaceutical Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009